Cargando…

基于雌激素受体信号通路的肺癌靶向治疗研究进展

Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ER...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999620/
https://www.ncbi.nlm.nih.gov/pubmed/21924040
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.07
_version_ 1783331454765236224
collection PubMed
description Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ERα-mediated signaling pathways in breast cancer, targeted therapy through these pathways have successfully been used in clinical application. Tamoxifen, the classic representative, is a selective estrogen receptor modulator (SERM). Along with the elucidation of the role of estrogen in the pathophysiology of lung cancer, targeted lung cancer treatment based on the ER signaling pathways is also gradually being applied and it could become an important part of the comprehensive treatment for lung cancer.
format Online
Article
Text
id pubmed-5999620
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59996202018-07-06 基于雌激素受体信号通路的肺癌靶向治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 Increasing evidence indicates that estrogen promotes tumor growth in both estrogen target organs and non-target organs. Estrogen regulates cell proliferation and differentiation via two different receptors, estrogen receptors α and β (ERα and ERβ). In recent decades, with the clarification of the ERα-mediated signaling pathways in breast cancer, targeted therapy through these pathways have successfully been used in clinical application. Tamoxifen, the classic representative, is a selective estrogen receptor modulator (SERM). Along with the elucidation of the role of estrogen in the pathophysiology of lung cancer, targeted lung cancer treatment based on the ER signaling pathways is also gradually being applied and it could become an important part of the comprehensive treatment for lung cancer. 中国肺癌杂志编辑部 2011-09-20 /pmc/articles/PMC5999620/ /pubmed/21924040 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.07 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
基于雌激素受体信号通路的肺癌靶向治疗研究进展
title 基于雌激素受体信号通路的肺癌靶向治疗研究进展
title_full 基于雌激素受体信号通路的肺癌靶向治疗研究进展
title_fullStr 基于雌激素受体信号通路的肺癌靶向治疗研究进展
title_full_unstemmed 基于雌激素受体信号通路的肺癌靶向治疗研究进展
title_short 基于雌激素受体信号通路的肺癌靶向治疗研究进展
title_sort 基于雌激素受体信号通路的肺癌靶向治疗研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999620/
https://www.ncbi.nlm.nih.gov/pubmed/21924040
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.07
work_keys_str_mv AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn
AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn
AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn
AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn
AT jīyúcíjīsùshòutǐxìnhàotōnglùdefèiáibǎxiàngzhìliáoyánjiūjìnzhǎn